Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cpx-351 + enasidenib
- Development stage
- Unknown
- Lead developer
- Jazz Pharmaceuticals
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous (CPX-351), Oral (enasidenib)
01
Overview
**CPX-351 + enasidenib** is a combination regimen of CPX-351—a liposomal encapsulation of cytarabine and daunorubicin at a fixed 5:1 molar ratio—and enasidenib, an oral inhibitor of isocitrate dehydrogenase 2 (IDH2). CPX-351 is designed to optimize the delivery and synergy of cytarabine (a nucleoside analog inhibiting DNA synthesis) and daunorubicin (an anthracycline inducing DNA damage), primarily for the treatment of acute myeloid leukemia (AML) with adverse or secondary features. Enasidenib targets mutant IDH2 enzymes, restoring normal cellular differentiation in IDH2-mutant AML. The combination is being evaluated in clinical trials for relapsed/refractory AML, especially in those with IDH2 mutations, as the dual approach may increase efficacy compared to either therapy alone[1][3].
- Other names
- daunorubicin + cytarabine liposome + enasidenib
02
Targets
CYP2C8 (Cytochrome P450 2C8)DNAOAT1 (Organic anion transporter 1)SLCO1B3 (Organic anion transporting polypeptide 1B3)OCT2 (Organic cation transporter 2)ABCB1 (P-glycoprotein)TOP2A (DNA topoisomerase II)UGT1A1 (UDP-glucuronosyltransferase 1A1)IDH2 (Isocitrate dehydrogenase [NADP], mitochondrial (mutant))
Beyond the preview
Go deeper on cpx-351 + enasidenib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cpx-351 + enasidenib.